Michael H. Mulroy, Director at Lineage Cell Therapeutics, Inc. (LCTX), bought 7,000 shares at $1.40 ($10K) on 2022-03-24, disclosed to the SEC on 2022-03-25.
Open-market purchase of $10k LCTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| AST | BUY | 2018-07-27 | $5K | — | Filing → |
| AST | BUY | 2018-06-27 | $5K | — | Filing → |
| AST | BUY | 2018-05-31 | $5K | — | Filing → |